Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-3 of 3

Sort by

Sort Order Select

Journal Articles

Phase 3 study (inMIND) of tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Clinical characteristics and outcomes of patients receiving second-line treatment

Ajay Gopal, Marek Trneny, Laurie Sehn, Julie Wu, Michael Arbushites, Oscar Bortolami, Stefano Luminari

Blood (2025) 146 (Supplement 1): 1819.

https://doi.org/10.1182/blood-2025-1819

Published: 2025

Journal Articles

Phase 3 study (inMIND) of tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Clinical characteristics and outcomes by age

Christina Poh, Francisco Hernandez-Ilizaliturri, Marek Trneny, Julie Wu, Philomena Colucci, Oscar Bortolami, Laurie Sehn

Blood (2025) 146 (Supplement 1): 3582.

https://doi.org/10.1182/blood-2025-3582

Published: 2025

Journal Articles

Phase 3 study (inMIND) of tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Clinical characteristics and outcomes of high-risk patients

Kai Huebel, Paolo Strati, Laurie Sehn, Julie Wu, Philomena Colucci, Oscar Bortolami, Christian Scholz

Blood (2025) 146 (Supplement 1): 5367.

https://doi.org/10.1182/blood-2025-5367

Published: 2025